Evidence map›Paper›PMID 35910798›Full record

ArticleTheranostics2022

Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.

Sweta Ghosh, Rajbir Singh, Zachary Matthew Vanwinkle, Haixun Guo, Praveen Kumar Vemula, Ajay Goel, Bodduluri Haribabu, Venkatakrishna Rao Jala

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sweta GhoshDepartment of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Rajbir SinghDepartment of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Zachary Matthew VanwinkleDepartment of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Haixun GuoDepartment of Radiology, Center for Predictive Medicine, University of Louisville, Louisville, KY, USA.
Praveen Kumar VemulaInstitute for Stem Cell Biology and Regenerative Medicine (inStem), GKVK campus, Bangalore, Karnataka 560065, India.
Ajay GoelDepartment of Molecular Diagnostics and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Bodduluri HaribabuDepartment of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Venkatakrishna Rao JalaDepartment of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
University of Louisville · USCity of Hope · USInstitute for Stem Cell Biology and Regenerative Medicine · IN

Funding

Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative IntravaginalP20GM125504 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Shirin Ghods · 2018 to 2026
$24.4M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
CCR2 mediated inflammation and gut microbiota in promoting intestinal cancerR21CA191683 · NCI · UNIVERSITY OF LOUISVILLE · PI JALA, VENKATAKRISHNA RAO · 2015 to 2016
$359k
NCI NIH HHS R21 CA191683NIEHS NIH HHS P30 ES030283NIGMS NIH HHS P20 GM125504
6 · The paper itself

Abstract

The survival rate of colorectal cancer patients is adversely affected by the selection of tumors resistant to conventional anti-cancer drugs such as 5-fluorouracil (5FU). Although there is mounting evidence that commensal gut microbiota is essential for effective colon cancer treatment, the detailed molecular mechanisms and the role of gut microbial metabolites remain elusive. The goal of this study is to decipher the impact and mechanisms of gut microbial metabolite, urolithin A (UroA) and its structural analogue, UAS03 on reversal of 5FU-resistant (5FUR) colon cancers.

Indexed as

Colonic NeoplasmsDrug Resistance, NeoplasmFluorouracilForkhead Box Protein M1Forkhead Box Protein O3Gastrointestinal MicrobiomeAnimalsAntimetabolites, AntineoplasticATP Binding Cassette Transporter, Subfamily G, Member 2AzoxymethaneCell Line, TumorCoumarinsHumansMiceNeoplasm Proteins3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneAntimetabolites, AntineoplasticATP Binding Cassette Transporter, Subfamily G, Member 2AzoxymethaneCoumarinsFluorouracilForkhead Box Protein M1Forkhead Box Protein O3FOXM1 protein, humanFoxm1 protein, mouseFOXO3 protein, humanFoxO3 protein, mouseNeoplasm Proteins5-FluorouracilChemoresistant colon cancerChemosensitizationdrug transportersFOXO3-FOXM1 axisMicrobial metaboliteUrolithin A

Identifiers

PMID35910798
PMCPMC9330515
OpenAlexW4285821576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.